To our knowledge, this is the largest study to date exploring atherosclerosis targets from an inflammation perspective, identifying nine potential therapeutic targets for CAS, excluding CD4 and AGER (lacking colocalization and replication evidence). This evidence concerns the gene CD4 and atherosclerosis.